Probatebeta
Target

VEGFA

Vascular endothelial growth factor A, long form

As of the edition of 20 October 2026, VEGFA (vascular endothelial growth factor A, long form, UniProt P15692) has 23 drugs tested at it and 32 companies on the list, 6 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P15692
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
57
Disease areas
Cancer; Digestive system; Eye; Hormones; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Skin and connective tissue
Registered trials of its drugs
3,275

Drugs at this target

StatusCount
Marketed8
Active8
Went quiet3
Stopped3
Status not established1
Total23
DrugStatusFurthest phaseUS protection
BevacizumabMarketedPhase 4Ends 2027
RanibizumabMarketedPhase 4Ended 2018
AfliberceptMarketedPhase 4Ends 2030
FaricimabMarketedPhase 4Ends 2034
BrolucizumabMarketedPhase 4Ends 2031
Pegaptanib sodiumMarketedPhase 4none listed
ConberceptMarketedPhase 4none listed
Abicipar pegolWent quietPhase 3none listed
MuparfostatStoppedPhase 3none listed
SuvemcitugActivePhase 3none listed
BI 836880StoppedPhase 2none listed
IBI302ActivePhase 3none listed

12 of 23 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A6
Route B5
Engaged15
Undetermined6
Total on the list32
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
AbbVieRoute A
Chengdu Kanghong BiotechRoute B

The other 29 companies at VEGFA

In the product

32 companies in all; 29 are not named here, and no score is.

See the 32 companies at VEGFA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at VEGFA

Other targets in cancer

Companies holding approvals at VEGFA